RARE
RARE
NASDAQ · Biotechnology

Ultragenyx Pharmaceutical In

Small-Cap Stocks Biotech Stocks Healthcare Stocks
$15.62
-1.54 (-8.97%)
As of Nov 5, 8:51 PM ET ·
RARE News3 articles
Ultragenyx Soars 12.6% on FDA Full Approval of Gene Therapy FAYUVI
Ultragenyx shares surged 12.6% after FDA full approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A. The company plans to launch within 30-60 days.
Markets
Oil Surges Past $92, Tech Futures Dip as Energy Gains Outweigh AI Optimism
Crude oil climbs above $92 a barrel, erasing earlier tech gains. Snowflake jumps 24% on strong results, while Ultragenyx drops 44% after a failed trial.
Markets
Ultragenyx Plunges 44% as Angelman Gene Therapy Fails Phase 3 Trial
Ultragenyx's stock plummeted 44% after its Phase 3 apazunersen trial failed, wiping out $1.14 billion in market cap. The company now faces major cost cuts.
Markets